IJCRR - Vol 05 Issue 02, January, 2013
NEW DRUG TARGETS TO TREAT THE OBESITY
Author: Dabhade Sanjay, Dabhade S.S., Tiwari S.A., Rane B.T. Meenakshi Sable
Background: The incidence of obesity is increasing dramatically to epidemic proportions. There are few approved anti-obesity pharmacological treatments and their modest efficacy and safety concern. Presently two drugs approved by US FDA for treatment of obesity are Phentermine and Orlistat.
Objective: The aim of this review is to discuss the new pharmacological agents that are under development and that may be eventually used for treatment of obesity.
Low doses of topiramate and phentermine: The rational for combining topiramate with phentermine is to minimise the required dose of each of the medication thereby opening up more than one pathway to satiety in hope of achieving great efficacy.
Bupropion and Naltriaxone: Monotherapy with bupropion shown weight loss of 2.8 kg at 52 weeks and this does not meet FDA criteria for an antiobesity drug. Naltriaxone alone is associated with minimal weight loss. Combination would be associated with weight reduction.
Zonisamide and Bupropion: Zonisamide induces weight loss as a side effect. It was thought that bupropion when added to zonisamide decreases the depressive and sedative properties associated with zonisamide while the latter might reduce the likelihood of bupropion-induced seizures.
Liraglutide: Victoza (liraglutide) is a once-daily version of the new-generation GLP-1(glucagon like peptide) analogs. Victoza reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake. Cetilistat: an inhibitor of pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. This drug is similar to the currently FDA-approved drug orlistat. Phase III trials of cetilistat are currently under way in Japan.
TTP 435:TTP435 is a potent and selective inhibitor of AgRP. TTP435 was shown to reduce food intake and body weight gain, reduce fat composition, and reduce insulin levels in a dose-dependent fashion.
GSK 598809: GSK 598809 is a D3 antagonist that blocks dopamine. It is thought that blocking dopamine may reduce the intake of foods high in fat and sugar.
Conclusion: Many factors have mitigated against active drug development, including the poor safety and efficacy of previous antiobesity drugs. The new generation of antiobesity drugs offers hope for the management of obesity, although no single agent is likely to be a solution.
Keywords: phentermine, fenfluramine, orlistat, obesity
Dabhade Sanjay, Dabhade S.S., Tiwari S.A., Rane B.T. Meenakshi Sable. NEW DRUG TARGETS TO TREAT THE OBESITY International Journal of Current Research and Review. Vol 05 Issue 02, January, 71-82
1. Paul F.Pilch and Nils Bergenhem, pharmacological targeting of adipocytes /fat metabolism for treatment of obesity and diabetes, Molecular Pharmacology 70:779- 78,2006
2. Zigman , Endotext.com-obesity,New molecular targets for the treatment of obesity, August 19,2003, online
3. Frank L.Greenway,M.J.Whitehouse,Maria Guttadauria, James W Anderson , Rational design of a combination medication for treatment of obesity. Obesity:17(1),30- 39,2008
4. Tim C. Kirkham,Endogenous cannabinoids:a new treatment of obesity . Am.J.Physiol Regul Integr comp physiol 284:R343- R344,2003
5. N.Finer, New targets for obesity pharmacotherapy –developing anti-obesity drugs that do not necessarily produce weight loss. ©2011 International association for the study of obesity .Clinical obesity1,61
6. Bruce J Sargent and Nicholas A Moore.New central targets for the treatment of obesity .British J Clin Pharmacology:68(6),82-860 Dec.2009
7. AG Powell,CM Apovion,LJ Aronne New drug targets for treatment of obesity ,Clin Pharmacol Therapeutics 90(1)40-50,2011
8. James WP et al ,SCOUT investigators Effect of sibutramine on cardiovascular outcome in overweight and obese subjects NEJM 363:(905)917-917(2010)
9. Gadde km ,Effects of low dose controlled release phenteramine plus topiramate combination on weight & associated comorbidities in overweight and obese adults (CONQUER):a randomised placebo controlled Phase 3 trial Lancet 377,1341- 1352,2011
10. Li,zet et al, Meta analysis: pharmacologic treatment of obesity , Ann of internal medicine 142,532-46,2005
11. Kishore M Gadde, Gretchen M Yonish, Mariko S Foust, H Ryan Wagner Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, openlabel study. The Journal of clinical psychiatry (2007) Volume: 68, Issue: 8, Pages: 1226- 1229
12. Goodman and Gilman’s The pharmacological basis of therapeutics 12th edition 397-415 13. Goodman and Gilman’s The pharmacological basis of therapeutics 12th edition 1238-1273
14. K.D.Tripathi Essentials of medical pharmacology 6 th edition116-131
15. Arne Astrup et al Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study The Lancet, Volume 374, Issue 9701, Pages 1606 - 1616, 7 November 2009.
16. RocheHolding AG and Ipsen SA ,Taspoglutide
17. Kopelman Development of a Novel AntiObesity and Anti-Diabetic Agent: Cetilistat, a Lipase Inhibitor, in Phase III Clinical Development. Diabetes Metabolism 55, A3952006.
18. Bello NT, Zahner MR Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. email@example.com.
19. Velneperit: Curr Opin Investig Drugs. 10(10):1105-1107,2009
20. Shinogi, Press releaseVelneperit,a novel NPY Y5 receptor antagonist being investigated for obesity
21. Zafgen.Press release ZGN433 in obesity
22. Wellcome trust.Press release PP1420 A breakthrough in appetite suppression .
23. Steensland P, Simms JA, Nielsen CK, Holgate J, Bito-Onon JJ, Bartlett SE.The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS One. 2010 Sep 1;5(9). pii: e12527.
24. Ribeiro MO.Effects of thyroid hormone analogs on lipid metabolism and thermogenesis. Thyroid: 18(2):197-203, Feb 2008/
25. Paul M. Stewart,Jeremy W. Tomlinson. Selective Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 for Patients with Metabolic Syndrome .Is the Target Liver, Fat, or Both?
26. Am. society for pharmacology and experimental therapeutics vol .70 no 3 ,2006,779-785
27. Huiyun Liang and Walter F. Ward PGC-1α: a key regulator of energy metabolism .Adv Physiol Educ 30:145-151, 2006© 2006 American Physiological Society
28. Expand+Kara M. Levri, , Elizabeth Slaymaker, , Allen Last, Juli Yeh, Jonathan Ference, Frank D’Amico, Stephen A. Wilson Metformin as Treatment for Overweight and Obese Adults: A Systematic Review: Ann Family Med September 1, 2005 vol. 3 no. 5 457-461
29. Min Hae Park, Sanjay Kinra,Kirsten J. Ward,Billy White ,Russell M. Viner, Metformin for Obesity in Children and Adolescents: A Systematic Review, Diabetes Care. 2009;32(9):1743-1745.